I don’t know, Orlando. But, I think you nailed i
Post# of 36501
![](/assets/46931549/no_avatar_available_thumb.jpg)
Excellagen is a bit like Oral-lyn. You can understand positive prospects, but for whatever reason no actual success or revenue. Yes, that could change with a better team, but prove something first. Gnbt already paid a hefty hefty premium vs. what Olaregen just recently paid for partial rights for Excellagen. That already takes a leap of faith for Gnbt shareholders, never mind raises and bonuses for Olaregen execs just as the acquisition occurs.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)